Revvity, Inc. (RVTY) Stock Analysis
Momentum Cont setup
Healthcare · Diagnostics & Research
Sell if holding. At $95.48, A.R:R 0.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 3.5%; Weak overall score: 5.0/10.
Revvity provides health science solutions across Life Sciences (instruments, reagents, software for drug discovery) and Diagnostics (screening, immunodiagnostics, reproductive health) segments marketed in 160+ countries. As of December 28, 2025, it employed ~11,000 employees.... Read more
Sell if holding. At $95.48, A.R:R 0.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 3.5%; Weak overall score: 5.0/10. Chart setup: Trend continuation, RSI 65, MACD bullish. Score 5.0/10, moderate confidence.
Passes 7/10 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 69d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Revvity, Inc.
Latest news
- Is Revvity Inc (RVTY) a Bargain After 3.4% Drop? GF Value Says U - GuruFocus — GuruFocus neutral
- Revvity, Inc. announces Quarterly dividend, payable on August 07, 2026 - marketscreener.com — marketscreener.com neutral
- Revvity (NYSE:RVTY) Hits New 52-Week Low - Time to Sell? - MarketBeat — MarketBeat negative
- Universal Beteiligungs und Servicegesellschaft mbH Sells 42,142 Shares of Revvity Inc. $RVTY - MarketBeat — MarketBeat negative
- Revvity Inc. stock underperforms Tuesday when compared to competitors - MarketWatch — MarketWatch negative
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $95.48, A.R:R 0.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 3.5%; Weak overall score: 5.0/10. Chart setup: Trend continuation, RSI 65, MACD bullish. Prior stop was $88.80. Score 5.0/10, moderate confidence.
Take-profit target: $98.87 (+3.6% upside). Prior stop was $88.80. Stop-loss: $88.80.
Thin upside margin: 3.5%; Weak overall score: 5.0/10; Weak growth.
Revvity, Inc. trades at a P/E of 45.9 (forward 16.4). TrendMatrix value score: 6.2/10. Verdict: Sell.
25 analysts cover RVTY with a consensus score of 3.8/5. Average price target: $114.
What does Revvity, Inc. do?Revvity provides health science solutions across Life Sciences (instruments, reagents, software for drug discovery) and...
Revvity provides health science solutions across Life Sciences (instruments, reagents, software for drug discovery) and Diagnostics (screening, immunodiagnostics, reproductive health) segments marketed in 160+ countries. As of December 28, 2025, it employed ~11,000 employees. Revenue comes from instruments, reagents, software, and related services sold to pharma, biotech, clinical labs, and research institutions.